Language selection

Search

Details for: JAKAVI

Company: NOVARTIS PHARMACEUTICALS CANADA INC

DIN DIN name Active Ingredient(s) Strength Dosage Form Route of Administration
02388006JAKAVIRUXOLITINIB (RUXOLITINIB PHOSPHATE)5 MGTABLETORAL
02434814JAKAVIRUXOLITINIB (RUXOLITINIB PHOSPHATE)10 MGTABLETORAL
02388014JAKAVIRUXOLITINIB (RUXOLITINIB PHOSPHATE)15 MGTABLETORAL
02388022JAKAVIRUXOLITINIB (RUXOLITINIB PHOSPHATE)20 MGTABLETORAL
Search Reported Side Effects Report a Side Effect

Summary Reports

Summary Basis of Decision
Regulatory Decision Summary
Summary Safety Review - Ruxolitinib - Assessing the potential risk of liver injury
Summary Safety Review - JAKAVI (ruxolitinib) - Assessing the potential risk of drug interactions with P-glycoprotein (P-gp) substrates (including rosuvastatin)
Summary Safety Review - Xeljanz and Xeljanz XR (tofacitinib) and Jakavi (ruxolitinib) - Janus Kinase (JAK) inhibitors - Assessing the Potential Risk of Blood Clots in the Deep Veins (Venous Thromboembolic Events)

Consumer Information

The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.

Date modified: